Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MB-106 |
Synonyms | |
Therapy Description |
MB-106 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD20, and containing CD28 co-stimulatory and TNFRSF9 (4-1BB) and CD3zeta signaling domains, which potentially induce killing of tumor cells expressing CD20 (Blood (2021) 138 (Supplement 1): 3872; NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MB-106 | MB 106|MB106 | CD20 Immune Cell Therapy 11 | MB-106 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD20, and containing CD28 co-stimulatory and TNFRSF9 (4-1BB) and CD3zeta signaling domains, which potentially induce killing of tumor cells expressing CD20 (Blood (2021) 138 (Supplement 1): 3872; NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05360238 | Phase Ib/II | MB-106 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | Terminated | USA | 0 |